Rheumaderm pp 49-54 | Cite as

Localized Morphea in Children

  • B. R. Krafchik
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 455)


We are following 60 patients with morphea and/or linear scleroderma at the Hospital for Sick Children, Toronto. Lesions may vary in depth from epidermal changes resembling lichen sclerosis, to superficial and deep dermal changes. The subcutaneous tissue, bone and muscle may be involved. There is no good clinical marker of the disease. Because of the variation in the time to cure, it is difficult to evaluate treatment regimens. We are currently using methotrexate weekly either orally or subcutaneously and monthly pulsed steroids for three months.


Borrelia Burgdorferi Lichen Sclerosus Progressive Systemic Sclerosis Porphyria Cutanea Tarda Poem Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    De Silva U, Parish LC: Historical approach to scleroderma. Clinics in Dermatol. 12: 201–205. 1994.CrossRefGoogle Scholar
  2. 2.
    Peterson LS, Nelson AM, Daniel WP: Subspecialty clinics: Rheumatology and dermatology. Classification of morphea (localized scleroderma). Mayo Clin Proc. 70: 1068–1076. 1995.PubMedCrossRefGoogle Scholar
  3. 3.
    Jablonska S: Scleroderma and pseudoscleroderma. 2nd Ed. Warsaw Poland: Polish Medical Publishers, pgs 537–546. 1975.Google Scholar
  4. 4.
    Buechner SA, Winkelmann RK, Lautenschlager S, Gilli L, Rufli T: Localized scleroderma associated with Borrelia burgdorferi infection. J Am Acad Dermatol. 29: 190–196. 1993.PubMedCrossRefGoogle Scholar
  5. 5.
    Birdi M, Shore A, Rush P, et al: Childhood linear slceroderma — A possible role of thermography for evaluation. J Rheumatol. 19: 968–973. 1992.PubMedGoogle Scholar
  6. 6.
    Meis JF, Koopman R, van Bergen B, Pool G, Melchers W: No evidence for a relation between Borrelia burgdorferi infection and old lesions of localized scleroderma (morphea). Letter to Editor. Arch Dermatol. 129: 386–387. 1993.Google Scholar
  7. 7.
    Rosenberg AM, Uziel Y, Krafchik BR, et al: Antinuclear antibodies in children with localized scleroderma. J Rheumatol. 22: 2337–2343. 1995.PubMedGoogle Scholar
  8. 8.
    Sato S, Ihn H, Soma Y, et al: Antihistone antibodies in patients with localized scleroderma. Arthritis Rheum. 36: 1137–1141. 1993.PubMedCrossRefGoogle Scholar
  9. 9.
    Takehara K, Moroi Y, Nakabayashi Y, Ishibashi Y: Antinuclear antibodies in localized scleroderma. Arthritis Rheum. 26: 612–616. 1983.PubMedCrossRefGoogle Scholar
  10. 10.
    Birdi N, Laxer RM, Thorner P, Fritzler MJ, Silverman ED: Localized scleroderma progressing to systemic disease. Case report and review of the literature. Arthritis Rheum. 36(3): 410–415. 1993.Google Scholar
  11. 11.
    Uziel Y, Krafchik BR, Feldman B, Silverman ED, Rubin LA, Laxer RM: Serum levels of soluble inter-leukin-2 receptor. A marker of disease activity in localized scleroderma. Arthritis Rheum. 37(6): 898–901. 1994.Google Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • B. R. Krafchik
    • 1
  1. 1.Department of DermatologyHospital for Sick ChildrenTorontoCanada

Personalised recommendations